ExploCap™ Technology
OZB ExploCap™ RNAs are produced by in vitro transcription and are co-transcriptionnaly capped using trinucleotides ExploCap analog (equivalent to CleanCap®) and contain a poly(A) tail at the 3’ end. Sequences have been optimized to yield improved stability and performance.
ExploCap™ is a next-generation co-transcriptional capping reagent designed to generate high-quality capped mRNA with excellent biological properties.
High-quality RNA capping plays a central role in mRNA & saRNA performance, as it directly impacts:
• RNA quality,
• translation efficiency,
• degradation risk by skipping a production step,
• downstream manufacturability.
ExploRNA’s next-generation capping reagent ExploCap™ has been designed to flexibly fit various in vitro transcription (IVT) workflows providing reliable high-quality outcomes. ExploCap™ supports both unmodified and modified RNA, and provides a cost-effective alternative to industry-standard capping reagents.
ExploCap mRNAs resemble fully matured mRNAs with 5’cap structure and 3’ polyA tail, therefore ready to be translated by the ribosome. ExploCap is a proprietary ExploRNA cap with properties similar to Cap 1.
| ARCA | CAP1 | ExploCap™ | CleanCap® | |
|---|---|---|---|---|
| Capping efficiency | 60-80% | 95-99% | 95-99% | 95-99% |
| Transcription Yield | Low | High | High | High |
ExploCap™ and CleanCap® show comparable mRNA transfection performance

Figure 1: DC2.4 cells transfected with GFP mRNA (100 ng/well, 96-well plate) using RmesFect transfection reagent at a 3.5 µl:1 µg ratio. Cells were analyzed after 24h of incubation.
CleanCap® is a proprietary technology of TriLink Biotechnologies.
ExploCap™ and Cap1 show comparable in vivo performance


Figure 2: mRNA: human EPO, non-modified U | Dose: 1 µg | Cap: Cap 1, ExploCap®. LNP: 3 different clinical grade formulations | Route: intravenous. Data provided by ExploRNA Therapeutics.
ExploCap™ technology is licensed to OZ Biosciences by ExploRNA Therapeutics and is protected under patent WO2021162566.
ExploCap is the intellectual property of ExploRNA Therapeutics.
All RNA products incorporating ExploCap are supplied for Research Use Only (RUO) and are not intended for diagnostic, therapeutic, or clinical use.

Explore our Webinar on mRNA platform: Explocap™, a new cap analog to extend synthesis capabilities
Discover our mRNA custom platform, with an overview of our synthesis capabilities and available modifications. ExploRNA Therapeutics introduce ExploCap™ and other cap analogs, supported by concrete in vivo data.
WatchCapped mRNAs
ExploCap™ mRNAs are available in unmodified, modified with 5moU or N1-mψ to reduce innate immune responses.
All our messenger RNAs catalog are available capped with ExploCap analog upon request.
ExploCap™ mRNA results
Comparison of transfection efficiency of mRNA capped with Cap1 and ExploCap™ in hek293 cells

Figure 3: HEK293 cultivated in 96-well plates were transfected with 100 ng mRNA encoding for GFP and capped with Cap1 or ExploCap™. 24 H after transfection, GFP expression was visualised under fluorescence microscopie (A) and fluorescence intensity was quantified by flow cytometry (B).
Comparison of transfection efficiency of mRNA capped with Cap1 and ExploCap™ in various cell lines (Vero, C6 and C2C12)


Figure 4: Vero C6 and C2C12 cell lines cultivated in 96-well plates were transfected with 100 ng mRNA encoding for GFP and capped with Cap1 or ExploCap™. 24 H after transfection, GFP expression was visualised under fluorescence microscopie (A) and % of GFP positive cells (B) and fluorescence intensity (C) were quantified by flow cytometry.
Capped saRNAs
ExploCap™ saRNAs are available in unmodified or modified with m5C.
All our self-amplifying RNAs catalog are available capped with ExploCap analog upon request.
ExploCap™ saRNA results
Comparison of transfection efficiency of saRNA capped with Cap1 and ExploCap in hek293 cells

Figure 4: HEK293 cultivated in 96-well plates were transfected with 100 ng saRNA encoding for GFP and capped with Cap1 or ExploCap™ using Rmesfect at a 3.5:1 ratio. GFP expression was visualised under fluorescence microscopie at day 1 (D1) and day 6 (D6) after transfection.
ExploCap™ GFP mRNA
Unmodified / 5-methoxyuridine / N1-methylpseudouridine
ExploCap™ OVA mRNA
Unmodified / 5-methoxyuridine / N1-methylpseudouridine
ExploCap™ Spike SARS CoV-2...
Unmodified / 5-methoxyuridine / N1-methylpseudouridine
ExploCap™ GFP saRNA
Unmodified / m5C
ExploCap™ F-Luc mRNA
Unmodified / 5-methoxyuridine / N1-methylpseudouridine








